VHCP Management III, LLC - Q4 2019 holdings

$504 Million is the total value of VHCP Management III, LLC's 18 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 100.0% .

 Value Shares↓ Weighting
PRVL ExitPrevail Therapeutics Inc$0-4,408
-100.0%
-0.03%
PTI ExitProteostasis Therapeutics Inc$0-221,267
-100.0%
-0.12%
RDUS ExitRadius Health Inc$0-23,131
-100.0%
-0.37%
KNSA ExitKiniksa Pharmaceuticals Ltd$0-277,137
-100.0%
-1.46%
TCDA ExitTricida Inc$0-80,348
-100.0%
-1.53%
BCRX ExitBioCryst Pharmaceuticals Inc$0-2,708,207
-100.0%
-4.79%
LJPC ExitLa Jolla Pharmaceuticals$0-1,251,898
-100.0%
-6.80%
RARX ExitRa Pharmaceuticals$0-670,350
-100.0%
-9.79%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-02-13
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Kalvista Pharmaceuticals6Q4 201921.5%
Obseva SA6Q4 201915.8%
Constellation Pharmaceuticals6Q4 201923.5%
Marinus Pharmaceuticals Inc6Q4 20195.1%
Bellerophon Therapeutics6Q4 20191.9%
BioCryst Pharmaceuticals Inc5Q3 201918.0%
Tricida Inc5Q3 201915.0%
Protagonist Therapeutics Inc5Q4 20198.0%
Kiniksa Pharmaceuticals Ltd5Q3 20196.7%
Axsome Therapeutics Inc4Q4 201931.8%

View VHCP Management III, LLC's complete holdings history.

Latest filings
TypeFiled
42024-02-22
42024-02-08
42024-02-01
42024-01-29
42024-01-24
42024-01-19
42024-01-16
42024-01-10
42024-01-05
42023-12-29

View VHCP Management III, LLC's complete filings history.

Compare quarters

Export VHCP Management III, LLC's holdings